T
Tom Böhling
Researcher at University of Helsinki
Publications - 194
Citations - 9120
Tom Böhling is an academic researcher from University of Helsinki. The author has contributed to research in topics: Merkel cell carcinoma & Comparative genomic hybridization. The author has an hindex of 48, co-authored 184 publications receiving 8365 citations. Previous affiliations of Tom Böhling include Helsinki University Central Hospital.
Papers
More filters
Journal ArticleDOI
MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas.
Netta Mäkinen,Miika Mehine,Jaana Tolvanen,Eevi Kaasinen,Yang Li,Heli J. Lehtonen,Massimiliano Gentile,Jian Yan,Martin Enge,Minna Taipale,Minna Taipale,Mervi Aavikko,Riku Katainen,Elina Virolainen,Tom Böhling,Tom Böhling,Taru A. Koski,Virpi Launonen,Jari Sjöberg,Jussi Taipale,Jussi Taipale,Pia Vahteristo,Lauri A. Aaltonen +22 more
TL;DR: It is determined that MED12 is altered in 70% (159 of 225) of tumors from a total of 80 patients, and aberrant function of this region of MED12 contributes to tumorigenesis.
Journal ArticleDOI
Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts.
Juha Paloneva,Marjo Kestilä,Jun Wu,Antti Salminen,Tom Böhling,Vesa Ruotsalainen,Panu Hakola,Alexander B. H. Bakker,Joseph H. Phillips,P. Pekkarinen,Lewis L. Lanier,Tuomo Timonen,Leena Peltonen +12 more
TL;DR: The molecular defect inPLOSL is characterized by identifying one large deletion in all Finnish PLOSL alleles and another mutation in a Japanese patient, both representing loss-of-function mutations in the gene encoding TYRO protein tyrosine kinase binding protein (TYROBP).
Journal ArticleDOI
Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
Stefano Ferrari,Sigbjørn Smeland,Mario Mercuri,Franco Bertoni,Alessandra Longhi,Pietro Ruggieri,Thor Alvegård,Piero Picci,Rodolfo Capanna,Gabriella Bernini,Christoph R. Müller,Amelia Tienghi,Thomas Wiebe,Alessandro Comandone,Tom Böhling,Adalberto Brach del Prever,Otte Brosjö,Gaetano Bacci,Gunnar Sæter +18 more
TL;DR: The addition of high- dose ifosfamide to methotrexate, cisplatin, and doxorubicin in the preoperative phase is feasible, but with major renal and hematologic toxicities, and survival rates similar to those obtained with four-drug regimens using standard-dose ifosFamide.
Journal ArticleDOI
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
Stefan S. Bielack,Sigbjørn Smeland,Jeremy Whelan,Neyssa Marina,Gordana Jovic,Jane Hook,Mark Krailo,Mark C. Gebhardt,Zsuzsanna Papai,James O. Meyer,Helen Nadel,R. Lor Randall,Claudia Deffenbaugh,Rajaram Nagarajan,Bernadette Brennan,G. Douglas Letson,Lisa A. Teot,Allen M. Goorin,Daniel Baumhoer,Leo Kager,Mathias Werner,Ching C. Lau,Kirsten Sundby Hall,Hans Gelderblom,Paul A. Meyers,Richard Gorlick,Reinhard Windhager,Knut Helmke,Mikael Eriksson,Peter M. Hoogerbrugge,Paula J. Schomberg,Per-Ulf Tunn,Thomas Kühne,Heribert Jürgens,Henk van den Berg,Tom Böhling,Susan Picton,Marleen Renard,Peter Reichardt,Joachim Gerss,Trude Butterfass-Bahloul,Carol D. Morris,Pancras C.W. Hogendoorn,Beatrice Seddon,Gabriele Calaminus,Maria Michelagnoli,Catharina Dhooge,Matthew R. Sydes,Mark L. Bernstein +48 more
TL;DR: Investigation of maintenance therapy with pegylated interferon alfa-2b in patients whose osteosarcoma showed good histologic response (good response) to induction chemotherapy found that MAP plus IFN-α-2B was not statistically different from MAP alone.
Journal ArticleDOI
Clinical Factors Associated With Merkel Cell Polyomavirus Infection in Merkel Cell Carcinoma
TL;DR: Findings lend support to the hypothesis that viral infection is frequently associated with the pathogenesis of Merkel cell carcinoma.